COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
- 31 January 2005
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 96 (1), 159-167
- https://doi.org/10.1016/j.ygyno.2004.09.050
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?European Journal of Cancer, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomasInternational Journal of Gynecologic Cancer, 2002
- Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomasInternational Journal of Gynecologic Cancer, 2002
- Cyclooxygenase‐2 expression in endometrial carcinomaCancer, 2002
- KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal TumorsThe American Journal of Pathology, 2000
- Smooth Muscle, Endometrial Stromal, and Mixed Müllerian Tumors of the UterusLaboratory Investigation, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- The kit ligand: A cell surface molecule altered in steel mutant fibroblastsCell, 1990
- Management of malignant, mixed mesodermal tumors of the uterusGynecologic Oncology, 1989